MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives $35.00 Consensus Price Target from Brokerages

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) have been given a consensus rating of “Hold” by the five brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $35.00.

INKT has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of MiNK Therapeutics in a research report on Monday, May 18th. Weiss Ratings cut shares of MiNK Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, June 17th. Finally, Wall Street Zen raised shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th.

Institutional Investors Weigh In On MiNK Therapeutics

An institutional investor recently raised its position in MiNK Therapeutics stock. Geode Capital Management LLC lifted its stake in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 14,247 shares of the company’s stock after purchasing an additional 1,441 shares during the quarter. Geode Capital Management LLC owned 0.30% of MiNK Therapeutics worth $159,000 as of its most recent SEC filing. 2.87% of the stock is currently owned by institutional investors and hedge funds.

MiNK Therapeutics Price Performance

Shares of INKT stock opened at $11.31 on Friday. The stock has a market cap of $56.32 million, a P/E ratio of -3.98 and a beta of 0.47. The company has a fifty day moving average price of $11.67 and a two-hundred day moving average price of $11.46. MiNK Therapeutics has a one year low of $6.80 and a one year high of $76.00.

MiNK Therapeutics (NASDAQ:INKT) last issued its earnings results on Friday, May 15th. The company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.20. As a group, equities research analysts anticipate that MiNK Therapeutics will post -2.75 EPS for the current fiscal year.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.